Cargando…
Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)
INTRODUCTION: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in central retinal vein occlusion. CASE REPORT: T...
Autores principales: | Coelho, João, Pessoa, Bernardete, Meireles, Angelina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322089/ https://www.ncbi.nlm.nih.gov/pubmed/30643869 http://dx.doi.org/10.1177/2515841418820755 |
Ejemplares similares
-
Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
por: Pessoa, Bernardete, et al.
Publicado: (2020) -
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
por: Mushtaq, Yusuf, et al.
Publicado: (2023) -
Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal
implant: outcomes from the ILUVIEN(®) clinical evidence study in
Portugal
por: Carneiro, Angela, et al.
Publicado: (2020) -
Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy
por: Meireles, A, et al.
Publicado: (2017) -
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)